Although, the C-7 bispecific VHH and cetuximab triggered a similar release pattern of TNF and cytotoxic molecules by NK cells, the use of a CD16 specific VHH provides several advantages compared to ADCC mediated through binding of the Fc domain of a therapeutic tumor-targeting antibody to CD16. The gene discussed is TNF; the disease is neoplasm.